Silexion Therapeutics Corp · NASDAQ:SLXN
Silexion Therapeutics — Investor Presentation (March 2025)
32 slides from Silexion Therapeutics's investor presentation, Mar 28, 2025
Slide 1: Silencing Oncogenes at the Level of Gene Expression
Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Corporate Presentation March, 2025
Slide 2: Forward-Looking Statements
The statements contained in this presentation that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future.
Slide 3: Company Overview
Company Overview Silexion’s siRNA platform technology is designed to silence oncogenes and prevent the production of the mutated KRAS proteins that drive cancer growth First generation, SiG12DLoder siRNA Completed Phase 2 clinical trial, shows strong trend for 9.3 months improvement in overall survi
Slide 4: KRAS Oncogene is a Validated Target for Numerous Cancers
KRAS Oncogene is a Validated Target for Numerous Cancers 4 Prevalence of The Most Common Types of KRAS Mutations Across Cancers CRC=colorectal cancer; LAPC=locally advanced pancreatic cancer; NSCLC=non-small cell lung cancer. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91. PDAC CRC Non-sq NSCLC Sma
Slide 5: Pancreatic Cancer Has One of the Highest Mortality Rates of All Major Cancers
Pancreatic Cancer Has One of the Highest Mortality Rates of All Major Cancers BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. 1. Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Fac
Slide 6: Innovatively Treating the Cancer-Driving KRAS at the Source and Site of Action
Innovatively Treating the Cancer-Driving KRAS at the Source and Site of Action Moving closer to treating the mechanism of the cancer more efficiently and with a greater chance to overcome treatment-resistance Cell proliferation Migration Transformation Survival Silexion siRNA Intratumor delivery KRA
Slide 7: Silexion Innovative Oncological Approach May Improve Outcomes Over KRAS Inhibitors
Silexion Innovative Oncological Approach May Lead to Significant Improvement in Clinical Outcomes Over KRAS Inhibitors Treatment resistance Low tolerability with adverse events such as rashes and GI side effects that require special monitoring Limited overall response rate and progression-free survi
Slide 8: SIL204 is the Most Advanced siRNA Formulation for LAPC With a Significant Market Opportunity
SIL204 is the Most Advanced siRNA Formulation for LAPC With a Significant Market Opportunity KRAS mutations are present in ~92% pancreatic cancer cases1 ROW=rest of the world. *Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancreatic cancer patien
Slide 9: LODER (First generation siRNA) Phase 2 Clinical Trial Data
LODER (First generation siRNA) Phase 2 Clinical Trial Data
Slide 10: Phase 2 Trial of Loder Completed in 2023 – a Proof-of-Concept
Phase 2 Trial of Loder Completed in 2023 – a Proof-of-Concept Two-part, open label, study of LODER + SoC chemotherapy vs SoC chemotherapy alone across the U.S. and Israel in patients with non-resectable pancreatic cancer SoC=standard of care. Arm 1: LODER + SOC Chemo (n=18) Day 0 Randomization Long-
Slide 11: Baseline Characteristics and Cohorts Information
Baseline Characteristics and Cohorts Information Due to results of a clinical trial indicating FOLFIRINOX’s advantage over GnP as SoC chemotherapy, cohort 2’s SoC chemotherapy was changed from GnP (used in cohort 1) to FOLFIRINOX. BRPC=borderline resectable pancreatic cancer; GnP=gemcitabine/nab-pac
Slide 12: Loder Treatment Led to Robust Objective Response Rate in LAPC Patients
Loder Treatment Led to Robust Objective Response Rate in Patients with LAPC Harboring G12D/V Mutations* LAPC=locally advanced pancreatic cancer. *Overall response rate was confirmed by RECIST 1.1 of the target tumor, as analyzed by sites. Bar curves below the solid black line starting at y-axis -0.3
Slide 13: Cohort 1 Patients Treated with Loder Had 9.3 Months Improvement in Overall Survival
Cohort 1 Patients Treated with Loder Had 9.3 Months Improvement in Overall Survival 13 * SoC (Control) OS consistent with recent trials for LAPC (Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347). Hazard ratio (HR)=0.59, (95% CI, 0.18, 1.96, p=0.39) Time to death is slower, 41% reduction in the ra
Slide 14: Phase 2 Safety Results: Serious Adverse Events
Phase 2 Safety Results Serious Adverse Events (SAEs) Related to Treatment in Patients with LAPC who Received LODER + Chemotherapy (treatment plus EUS-endoscopy administration procedure) LODER + SOC chemo (n=38) SAE All grades n (%) Grades 3-4 n (%) Gastrointestinal disorders 3 (8%) 2 (5%) Hematemesi
Slide 15: LODER Was Overall Well Tolerated
LODER Was Overall Well Tolerated The Phase 2 PoC clinical trial investigators reported that LODER treatment was well tolerated; Safety events were primarily related to procedure Intratumor administration of extended-release siRNA via endoscopy (EUS) is safe No Treatment Emergent Adverse Events (TEAE
Slide 16: Optimizations Allow Comprehensive Approach: Systemic and Intratumor Administrations
Optimizations allows for comprehensive approach: systemic and intratumor administrations siRNA: Successful preclinical results in metastatic models with subcutaneous administration and primary tumor models with intratumor administration Enhanced stability Broadening silencing activity
Slide 17: Leveraging LODER Clinical Data to Further Improve SIL204 Potential Efficacy and Safety
Leveraging LODER Clinical Data to Further Improve SIL204 Potential Efficacy and Safety 17 HR=Hazard Ratio. *EUS endoscopy is a standard procedure used to obtain ultrasound guided biopsies once every 3 months. ` LODER SIL-204 siRNA target KRAS G12D/V+ KRAS amplify KRAS G12D/V+ KRAS amplify, potential
Slide 18: SIL204 Shows Broad Inhibition Across Human KRAS Mutations at Sub-Nanomolar Concentrations
SIL204 Shows Broad Inhibition Across Human KRAS Mutations at Sub-Nanomolar Concentrations SIL204 maintains and expands the silencing activity of the siG12DLoder 18 Model is a co-transfection setup where human KRAS is transfected in mouse Hepa1-6 cells with Dual-Glo reporter plasmids. Mutation Negati
Slide 19: SIL204 is Stable In Vitro for Over 48 Hours in Human Serum
SIL204 is Stable In Vitro for Over 48 Hours in Human Serum 19 siRNA strand placed in human serum and tested for stability Stability of siRNA Strand in Human Serum Potentially longer effectiveness of siRNA Greater ability to diffuse throughout the fibrous tumor environment Potential in other indicati
Slide 20: SIL204 Remains at Substantial Levels for >56 Days in Plasma and Tissues
SIL204 Remains at Substantial Levels for >56 Days in Plasma and Tissues Single subcutaneous administration SIL204 solution (10mg, not formulated) to Sprague Dawley rats 20 Potential for longer effectiveness of siRNA for treating micrometastases with clinical dosing on monthly basis
Slide 21: SIL204 Behaves Synergistically with Fluorouracil and Irinotecan-Containing Chemotherapy
SIL204 Behaves Synergistically with Fluorouracil and Irinotecan-Containing Chemotherapy *p<0.05; ** p<0.005; ***p<0.0005 Basis for first line chemotherapy for pancreatic cancer. Preclinical study measuring confluence of the human pancreatic cell line Panc-1 containing a G12D KRAS Mutation 21 *** **
Slide 22: Intratumor Administered SIL204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice
Intratumor Administered SIL204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice *p<0.05 ; ***p<0.0005 S.C. = sub cutaneous. SIL204 significantly reduced tumor volume and growth while increasing tumor necrosis (cell death) Day 1: Capan-1 (KRAS G12V) luciferase cells were xenografted to mice
Slide 23: Systemic Administration of siRNA Strongly Supported by Preclinical Data
Systemic Administration of siRNA Strongly Supported by Preclinical Data 23 Subcutaneous SIL204 Proved Effective in Mouse Metastatic Pancreatic Orthotopic Models Animal model represents human equivalent dose of SIL-204 High dosage subcutaneous injection of SIL204 ablated xenograft tumor * Human tumor
Slide 24: Systemic Administration of siRNA Strongly Supported by Preclinical Data
Systemic Administration of siRNA Strongly Supported by Preclinical Data 24 Subcutaneous SIL204 Proved Effective in Mouse Metastatic Pancreatic Orthotopic ModelsAnimal model represents the human equivalent dose of SIL-204 Low dosage subcutaneous injection of SIL-204 inhibited tumor growth * Human tum
Slide 25: Systemic Administration of siRNA Strongly Supported by Preclinical Data
Systemic Administration of siRNA Strongly Supported by Preclinical Data 25 Subcutaneous SIL204 Proved Effective in Mouse Metastatic Pancreatic Orthotopic Models Animal model represents human equivalent dose of SIL-204 * Human tumor cell line BxPC-3 Control Low dose SIL204
Slide 26: SIL204 Development Strategy in LAPC
SIL204 Development Strategy in LAPC 2023 2024 H1 2025 H2 2025 H1 2026 H2 2026 Clinical proof of concept for Loder in LAPC in an approvable endpoint for FDA Optimization of siRNA on various fronts; selection of SIL-204 Received guidance on trial design from the German Federal Institute for Drugs and
Slide 27: Focused Pipeline to Address KRAS-driven Solid Tumor Localized Cancers
Program Indication Setting Discovery Preclinical Phase 1 Phase 2 Phase 3 Status/ Anticipated Milestone LODER siG12D + KRAS amplify with extended release PLGA delivery system Locally advanced pancreatic cancer Adjunct to chemotherapy Phase 2 completed: observed 9.3 months improvement with LODER over
Slide 28: Strong Intellectual Property Protection
Strong Intellectual Property Protection Exclusivity can be extended under country-specific regulatory-based extension rules. Submissions Term Patents supporting siG12DLoder 10 patents issued world-wide, 6 patients pending. Protection until 2030 plus extension Patents supporting SIL204 Inhibition of
Slide 29: World-Renowned Expert Scientific Advisory Board
World-Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul, MD
Slide 30: Highly Experienced Leadership Team
Highly Experienced Leadership Team Ilan Hadar, MBA Chairman and Chief Executive Officer > 25 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer > 30 years of experience in R&D, inn
Slide 31: Investment Highlights
Investment Highlights CTA=clinical trial application; IND=investigational new drug. Clinical-stage company with proprietary oncogene silencing siRNA platform Phase 2 clinical trial with first generation Loder in LAPC showed strong trend for 9.3 months improvement in survival Second generation SIL204
Slide 32: Thank You
Thank You Nasdaq: SLXN Ilan Hadar Chairman & Chief Executive Officer email: ihadar@silexion.com Dr. Mitchell Shirvan Chief Scientific and Development Officer email: mshirvan@silexion.com Mirit Horenshtein Hadar, CPA Chief Financial Officer email: mirit@silexion.com
Silexion Therapeutics — Investor Presentation (March 2025) on 6ix